medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2012, Number 2

<< Back Next >>

Acta Med 2012; 10 (2)

The assessment of natalizumab efficacy and safety in the treatment of relapsing-remitting multiple sclerosis patients in the Hospital Angeles Pedregal

Canché-Arenas A, Violante-Villanueva A

Language: Spanish
References: 33
Page: 72-79
PDF size: 372.30 Kb.


ABSTRACT

Introduction: Multiple sclerosis (MS) and chronic disabling disease of the CNS, where inflammatory lesions can be multiple and widely distributed, leading to areas of demyelination and axonal degeneration. The monoclonal antibody natalizumab, blocks integrin alpha-4-beta-1, adhesion molecule expressed on lymphocyte surface, necessary for migration to the peripheral blood to the CNS, is a disease-modifying treatment for patients with high disease activity despite treatment with beta interferon or with rapidly progressive MS. Purpose of study: To evaluate the effectiveness of natalizumab in the treatment of multiple sclerosis. Material and methods: Observational, prospective, open from 9 patients treated with natalizumab December 2009-January 2011. Treatment: 300 mg natalizumab monthly. Response criteria: assessment of progression of disease outbreaks, evaluation of magnetic resonance imaging features of CD19 and CD4. Results: Natalizumab has a different mechanism of action to other drugs, thus providing an alternative for patients refractory to conventional treatments. Conclusions: The effectiveness and safety obtained in our patients suggest that an alternative for refractory patients with aggressive forms of multiple sclerosis.


REFERENCES

  1. Bradl M, Lassmann H. Progressive multiple sclerosis. Semin Immunopathol 2009; 31(4): 455-465.

  2. Shams PN, Plant GT. Optic neuritis: a review. Int MS J 2009; 16(3): 82-89.

  3. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33(11): 1444-1452.

  4. Cadavid D, Tang Y, O’ Neil G. Sensibilidad de la escala ampliada del estado de discapacidad (EDSS) a la progresión de la enfermedad y la intervención terapéutica en las formas progresivas de la esclerosis múltiple. Rev Neurol 2010; 51: 321-329.

  5. Fernández-Megía MJ, et al. Evaluación de la efectividad y la seguridad del natalizumab en el tratamiento de la esclerosis múltiple remitente recidivante. Farm Hosp. 2011. doi:10.1016/j.farma.2010.02.003

  6. Jacobs LD, Wende KE, Brownscheidle CM et al. A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium. Mult Scler 1999; 5(5): 369-376.

  7. Noseworthy JH et al. Medical progress: multiple sclerosis. N Engl J Med 2000; 343: 938.

  8. Lucchinetti C et al. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707.

  9. Berger T et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003; 349: 139.

  10. Archelos JJ et al. The role of B cells and autoantibodies in multiple sclerosis. Ann Neurol 2000; 47: 694.

  11. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol 2008; 7(12): 1139-1151.

  12. Kallaur AP, Kaimen-Maciel DR, Kaminami MH, Ehara WMA, Murilo GS, Reiche EM. Genetic polymorphisms associated with the development and clinical course of multiple sclerosis. Int J Mol Med 2011; 28(4): 467-479.

  13. National Multiple Sclerosis Society. Symptoms. Available in: http://wwwnationalmssociety.org/about-multiple-sclerosis/what-we-knowabout-ms/symptoms/index.aspx.

  14. Filippi M, Rocca MA. The role of magnetic resonance imaging in the study of multiple sclerosis: diagnosis, prognosis and understanding disease pathophysiology. Acta Neurol Belg 2011; 111(2): 89-98.

  15. Putzki N, Yaldizli O, Tettenborn B, Diener HC. Multiple sclerosis associated fatigue during natalizumab treatment. J Neurol Sci 2009; 285(1-2): 109-113.

  16. Thompson AJ. Progress in neurorehabilitation in multiple sclerosis. Curr Opin Neurol 2002; 15: 267-270.

  17. Alusi SH, Worthington J, Glickman S, Bain PG. A study of tremor in multiple sclerosis. Brain 2001; 124: 720-730.

  18. Koch M, Mostert J, Heersema D, De Keyser J. Tremor in multiple sclerosis. J Neurol 2007; 254: 133-145.

  19. Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci 1994; 21(1): 9-14.

  20. Hallett M, Berardelli A, Matheson J, Rothwell J, Marsden CD. Physiological analysis of simple rapid movements in patients with cerebellar deficits. J Neurol Neurosurg Psychiatry 1991; 54: 124-133.

  21. Gholipour T, Healy B, Baruch NF, Weiner HL, Chitnis T. Demographic and clinical characteristics of malignant multiple sclerosis. Neurology 2011; 76(23): 1996-2001.

  22. McDonald et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International panel of Multiple Sclerosis. Ann Neurol 2001; 50 (11): 121-127.

  23. Miller DH, Khan OA, William A. A Controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23.

  24. Rudick RA, Miller D, Hass S et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 2007; 62(4): 335-346.

  25. Amezcua L, Lund B, Weiner L, Islam T. Multiple sclerosis in Hispanics: a study of clinical disease expression. Mult Scler 2011; 17(8): 1010-1016.

  26. Polman CH, O’Connor PW, Havrdova E et al. AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354(9): 899-910.

  27. Prescott JP, Factor S, Pill MW, Levi GW. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007; 13(1): 44-52.

  28. Rajagopalan K, Agarwal S, Hou L, Kamat S, Stephenson J. What do multiple sclerosis patients experience? Effect of natalizumab on disease-specific quality of life over time. Mult Scler 2009; 15: S1267.

  29. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006; 66: 1696-1702.

  30. National Multiple Sclerosis Society. Epidemiology of MS. Available in: http://www.nationalmssociety.org/about-multiple-sclerosis/what-weknow-about-ms/who-gets-ms/epidemiology-of-ms/index.aspx

  31. www.nejm.org

  32. Foley J. Recommendations for the selection, treatment, and management of patients utilizing Natalizumab therapy for multiple esclerosis. Am J Manag Care 2010;16:S178-S183.

  33. Pelegrín MMA, Gómez-Conesa A. Quality of life questionnaires for multiple sclerosis. Fisioterapia 2002; 24(2): 56-62.




2020     |     www.medigraphic.com